Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Sixteen years ago, there were no licensed treatments for multiple sclerosis (MS). Today, there are six Food and Drug Administration-approved therapies, with more on the horizon. Over the past few years a significant number of these new therapies have failed to fulfil their promise, but unanticipated developments have come to light that have spurred the development of ever more new approaches to therapy. It is clear that the pace of development in the MS field has been rapid and continues to accelerate, making the prediction of factors that will impact on clinical practice ever more critical.

Type

Journal article

Journal

International MS Journal

Publication Date

01/12/2009

Volume

16

Pages

67 - 70